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Summary
Peripheral blood monorytes can be induced by stimuli such as bacterial lipopolysaccharide (LPS)
to secrete an array of cytokines. We have studied the effects of interleukin 7 (IL7) on human
peripheral blood mononuclear cells (PBMC) and found that IL-7 is a relatively potent inducer
of IL6 secretion. 11,6 protein levels were determined either by the B9 hybridoma growth factor
assay or by enzyme-linked immunosorbent assay, and mRNA for IL-6 was analyzed by Northern
hybridization. Detailed examination revealed that, among PBMC, monocytes, rather than
lymphocytes, were secreting IL-6 in response to IL-7. In contrast to the low concentrations of
IL-7 required to stimulate T cell growth and differentiation (as low as 0.1 ng/ml), relatively
high concentrations of IL7 were necessary to induce 11,6 secretion by monocytes (at least 10
ng/ml). An optimal concentration of IL-7 (100 ng/ml) induced monorytes to secrete 10-fold
more 11,6 than an optimal concentration of IL10 (10 ng/ml), and almost as much as LPS. However,
significantly more IL7 than IL1/3 was required to induce detectable levels of IL6. The kinetics
of IL6 secretion by monocytes were identical in response to IL-7, IL1/3, or LPS, with IL6 protein
detectable in culture supernatants as early as 2 h after the initiation of culture. IL4 was found
to markedly inhibit the ability of 11,7 or LPS to induce 11,6 mRNA and IL6 secretion. In addition
to promoting IL-6 production, IL-7 induced the secretion of immunoreactive IW01, IL-10, and
tumor necrosis factor ci (TNF-(x) by monocytes. IL7 also induced monocyte/macrophage
tumoricidal activity against a human melanoma cell target, an activity that may be related to
the secretion of ILW, IL10, and TNF-a. Finally, we used a whole blood culture system as
a bridge to in vivo analysis to demonstrate that 11,7 induces cytokine secretion in the absence
of culture medium, fetal calf serum, and adherence to plastic. Our data suggest that IL7, in
addition to regulating lymphocyte growth and differentiation, has potent effects on cells of the
monocytic lineage. Thus, IL-7 may be an important mediator in inflammation and in the macrophage
immune response to tumors.
A primary function of peripheral blood monorytes is the
regulated synthesis and secretion of an array ofbiologi-
cally active molecules including enzymes, plasma proteins,
and cytokines. Monocyte-derived cytokines include IL1a,
11,113, 11,6, 11,8, and TNF-a, all of which have broad im-
munoregulatory properties and are central to the host response
to infection (1-4). Microbial products such as LPS and pep-
tidoglycan are the most effective inducers of cytokine secre-
tion by monorytes. More recently, cytokines themselves have
been demonstrated to regulate monocyte rytokine synthesis
(5-13). In particular, IL1a, IL10, TNF-ci, TGF-(3, IFN-'y,
granulocyte/macrophage CSF (GM-CSF)t, and 11,3 have all
1 Abbreviations used in thispaper. GM-CSF, granulocyte/macrophage colony-
stimulating factor; LAK, lymphokine-activated killer cell.
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been shown to stimulate some aspect of monocyte rytokine
secretion, either acting alone or in combination with other
stimuli. Conversely, 114 has potent antagonistic effects on
the induction of monocyte activation, including both rytokine
secretion and respiratory burst activity (4, 8, 9, 14-17) .
IL7 is a stromal cell-derived cytokine that has a number
of effects on lymphocytes. IL7 stimulates the growth ofpre-
B cells, thymocytes, and mature T cells, and enhances the
generation of CTL and lymphokine-activated killer cells
(18-24). Receptors for IL-7 have also been demonstrated on
myeloid cells (25), however, until now, no activity for IL7
on monorytes/macrophages or neutrophils has been reported.
In this study, we found that IL7 has potent effects on cells
of the monocytic lineage. 11,7 stimulated the secretion of
cytokines including IL-6, ILIot, IL1#, and TNF-ot from
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monocyte/macrophage tumoricidal activity. Theseresults im-
plicate 1177 as an important regulator of inflammation by in-
ducing thesecretionofcytokinesthat arecentral to theinflam-
matory process.
Materials and Methods
Preparation ofCellsandCell Cultures.
￿
PBMC were isolated from
heparinized bloodby centrifugation over Ficoll-Hypaque. Mono-
cytes were enriched by counter current elutriation of PBMC fol-
lowed by adherence to plastic. Briefly, elutriator enriched mono-
cyteswere cultured at 2 x 105 cells in 16-mm wells (3524; Costar,
Cambridge, MA) in 1 ml of culture medium. After 90 minof in-
cubation at 37°C, nonadherent cells were removed by gentle
washing and replaced with fresh culture medium. The elutriated
cells were 90-95% monocytes by microscopic examination of
Giemsa-stained cytospin preparations and 80-85% CD14+ by flow
cytometry. Culturemedium consistedoflowendotoxinRPMI 1640
(Whittaker M.A. Bioproducts, Walkersville, MD) supplemented
with 10% low endotoxin FCS (Cellect Gold; Flow Laboratories,
McLean, VA), 50 U/ml penicillin, 50 ug/ml streptomycin, and
5 x 10-5 M 2-ME.
Cytokines. Cytokine preparations used in this study were
selected on thebasis oftheir low endotoxincontent. Allcytokines
contained <1 pg of endotoxin per microgram of protein, except
IIAcx whichcontained 3 pg, as determined by theLimulus amebo-
cyte lysate assay (Whittaker M.A. Bioproducts). IL7was purified
from Escherichia coli expressing a human 11,7 cDNA, as described
previously (23). IL7 had a specific activity of 3 x 10' U/ug in
themurine pre-B cell assay(18). IIAcaandIL10 were purified from
E. coli expressing human ILla or 11,10cDNAsas described previ-
ously (26) and had specific activities of 1.9 x 106 and 2.2 x 106
U/ug, respectively,in thethymocytecostimulationassay. I1'4 was
purified from the supernatant of yeast cells expressing a human
11,4 cDNA and had a specific activity of 10^ U/hg in a B cell
comitogenesisassay (27, 28). GM-CSF waspurified from yeastcells
expressing a human GM-CSF cDNA and had a specific activity
of 5 x 10" U/hg in a human bone marrow proliferation assay.
OtherReagents.
￿
LPS from Salmonella typhimurium was purchased
from DifcoLaboratories Inc. (Detroit, MI) and used at 10 ug/ml.
11,6, ILlox IL1O, and TNFtx Assays.
￿
11,6 bioactivity in cul-
ture supernatants wasdetermined using theIL6-dependent B9 hy-
bridoma growth factor assay (3). Briefly, thrice-washed B9 cells
were addedto serial dilutions oftest supernatants in 0.2 ml of RPMI
1640 (Gibco Laboratories, GrandIsland, NY) supplemented with
10% FCS (HyClone Laboratories, Logan, UT) in 96-well flat-
bottomed plates (Costar). Sampleswere assayed in duplicate. After
3 d, cell proliferation was assessed by ['H]thymidine (1 P.Ci/well)
incorporation during a6-h incubation. One unit of 11,6 is defined
as theamount required forhalf-maximal stimulation ofB9 prolifer-
ation. 11,6 wasalso assessed by an ELISA specific for human IL6.
ELISA plates (Corning Glass Works, Corning, NY) were coated
overnight at 4°C with 5 Ftg/ml of a murine mAb against human
IL6. After blocking with a5% solution ofnonfat drymilk in PBS,
test supernatants were serially diluted in PBSwith 10% goat serum
and incubated for 1 h at room temperature. Plates were washed
and a rabbit antiserum raised against human 11,6 was added at
1:1,000 dilution in PBS/20% goat serum. After a further hour at
room temperature, ahorseradish peroxidase coupledgoat anti-rabbit
Ig (Sigma Chemical Co., St. Louis, MO) at 1:2,000 dilution in
PBS/5% nonfat dry milk was added. Afterwashing, the substrate
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3,3;5,5'-tetramethylbenzidine (Kirkegaard & Perry Laboratories,
Gaithersburg, MD)wasaddedand absorbance ofwellsdetermined
1 h later using a Dynatech ELISA reader. IL6 concentrations in
test samples were determined by comparing titration curves with
titrations of a standard human 11,6 preparation (R & D Systems,
Minneapolis, MN)usingtheDeltaSoft 1.8 ELISAanalysis program
(Biometallics Inc., Princeton, NJ).
Urla concentrations in test supernatants were also determined
by ELISA. The II.1tx ELISA was identical to the 11,6 ELISA ex-
cept that thecoating mAb and second step rabbit antiserum were
specific for human IIAce instead of IL6.
TNF-a and IL10 concentrations were determined using com-
mercial ELISA kits (R & D Systems), as per the manufacturers
protocol.
Northern Blot Analysis ofIL6 mRNA.
￿
Totalcellular RNAwas
isolated as previously described(29). 10 Rg ofRNA was separated
on 1% agarose/6% formaldehyde gels, transferred to nylon filters
(Hybond; Amersham Corp., Arlington Heights, IL) and stained
by methyleneblue to ensure equal loading in each lane. Afterpre-
hybridization, the filters were hybridized at 63°C in a buffer con-
taining 5x SSC/10x Denhardt's/50% formamide for 18 h, at
which time the filters were washed first in 1x SSC/0.1% SDS,
then 0.lx SSC/0.1% SDS, at 68°C. The filters were then sub-
jected to autoradiography.
An antisense RNA transcript was synthesized from a human
111,6 cDNA using '1P-UTP (Amersham Corp.) andT3 RNA poly-
merase (Promega Biotec, Madison, WI) and was used for probing
IL6 mRNA from Northern blots.
Monocyte-Macrophage-Mediated TumoricidalAssay.
￿
The ability of
monocytes/macrophages to lyse A375 human melanoma cells was
assessed as previously described (30, 31). Target A375 cells were
labeled for 24 h with ['H]thymidine and added to 24 h mono-
cyte/macrophage cultures. After 24 h, culture supernatants were
removed and replaced with fresh medium and then cultured for
an additional 48 h. The cultures were then washed twice with
medium andcells lysed with 0.1% NP-40 in PBS. Lysed cellswere
then harvested for liquid scintillation (a) counting. Percent cyto-
toxicity was calculated from the following formula: percent cyto-
toxicity = 100x [1-(cpm test/cpm control)] ; where cpmcontrol
represents counts perminute of target cellscultured with untreated
monocytes, and cpm test represents counts per minute of target
cells cultured with cytokine-treated monocytes.
Whole Blood Cultures.
￿
Heparinized whole blood was cultured
in polypropylene tubes (Falcon 2005; Becton Dickinson & Co.,
Mountain View, CA) at 2 ml per tube in the presence or absence
of various stimuli, as previously described (32, 33). After 24 h of
incubation at 37°C in a humidified atmosphere of 5% COZ in air,
plasma was separated by centrifugation at 700g for 10 min and
filtered through0 .45-AM millipore filters. Cytokine levels were de-
termined by ELISA, as described above.
Results
IL7Stimulates 11,6 Secretion by HumanPeripheralBloodMono-
cytes. Initially, we observed that supernatants from PBMC
cultures stimulated with 11,7 for36 h contained elevated levels
of IL-6 compared to control noncytokine supplemented cul-
tures (Table 1). Culture supernatants were assessed for the
presence of IL-6 by the ability to cause the proliferation of
theIL-6-dependent B9 hybridomacell line (3). BecausePBMC,
in particular monocytes, are exquisitely sensitiveto endotoxinwith regards to IL6 secretion, all reagents used in this study
were selected for their low endotoxin levels . In addition we
found that heating IL -7 to 100°C for 30 min totally abol-
ished its ability to induce IL-6 secretion by PBMC, whereas
heating of LPS had no effect on its activity (data not shown) .
Monocytes, T cells, and B cells have all been shown to
secrete IL6, though monorytes appear to represent the major
cellular source in human peripheral blood (3, 34) . To deter-
mine what cells were being stimulated by IL-7 to secrete IL6,
we separated PBMC into populations enriched for mono-
cytes and T cells (Exp. 1), or monorytes and lymphocytes
(Exp. 2), as shown in Table 1 . PBMC were subjected to counter
current elutriation and divided into lymphocyte- and
monocyte-enriched fractions, basedupon microscopic exami-
nation of Giemsa-stained cytospins . In Exp . 1 the lympho-
cyte fraction was further enriched for T cells by E-rosetting,
and in Exp. 2 the lymphocyte fraction was further depleted
of monorytes by two cycles ofplastic adherence. The mono-
cyte fraction after further enrichment by plastic adherence
contained 90-95% monorytes by examination of Giemsa-
stained cytospins and 85-90% CD14+ cells by flow cytom-
etry whereas the lymphocyte fraction contained <1%
CD14+ cells. The data in Table 1 demonstrate that after
stimulation with IL7, IL1a, IL10, or LPS, the vast majority
of IL-6 was secreted by the monocyte-enriched population,
with little activity coming from the lymphocyte or T cell
populations . However, T cells did secrete high levels of IL-6
after 5 d of incubation with the combined stimulus ofPMA
plus PHA, as previously reported (reference 34 ; data not
shown), thus confirming the capability ofT cells to secrete
IL-6 . Table 1 also indicates that LPS was the most potent
stimulus for monocyte IL-6 production, followed by IL-7, IL
1a, and IL1(3 .
11,7 StimulatesIL6mRNA in Monocytes.
￿
To examine the
effects of 11,7 on IL-6 gene expression,we assessed IL-6mRNA
levels by Northern analysis after culturing monorytes with
Monocyte- and lymphocyte-enriched cell populations were isolated from PBMC by elutriation . T cells were further enriched from lymphocytes by
E-rosetting and monocytes enriched by plastic adherence, as described in Materials and Methods . PBMC, lymphocytes, and T cells were cultured
at 106/ml and monorytes at 2 x 105/ml in the presence of various stimuli for 36 h . Supernatants were collected and assessed for IL-6 bioactivity
in the B9 assay (3) .
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various stimuli for 4 h . Fig. 1 demonstrates that IL7, IILla,
IIL10, and LPS all stimulated significant IL-6 mRNA accumu-
lation in monocytes, whereas in cells cultured inmedium alone,
IL-6mRNA was not detectable. In agreement with our IL6
secretion data (Table 1), the level of IL -6mRNA expression
induced by IL-7 was greater than that induced by IL1(3, though
slightly less than that induced by LPS.
Dose-Response of11,7 Induction of IL6 Secretion .
￿
IL7 and
IL1/3 were compared for their ability to induce IL -6 secre-
Figure 1 .
￿
110 induces IL-6mRNA in monorytes. Monocytes were cul-
tured with medium alone, ILla (100 ng/ml),11,10 (100 ng/ml), IL7 (100
ng/ml), or LPS (10 ug/ml) . After 4 h RNA was extracted and Northern
analysis was performed with an 11,6 antisense RNA transcript probe .
Table 1 . IL-7 Induces IL-6 Secretion by Monocytes
IL-6
Exp . 1 Exp . 2
Stimulus PBMC Monocytes T cells PBMC Monocytes Lymphocytes
U/ml
Medium 19 15 <1 <1 <1 <1
IL-la ND ND ND 654 894 40
IL-10 ND ND ND 272 276 10
IL-7 3,067 5,654 11 1,895 2,437 49
LPS ND ND ND 1,353 >10,000 107J
tion by monorytes. IL6 levels were assessed by either the B9
hybridoma growth factor assay (Fig. 2 A) or by ELISA (Fig.
2 B). IL-7 induced significant IL6 production when used at
concentrations of 10 ng/ml or greater, though optimal IL-7
activity was observed at 100 ng/ml. In contrast, IL10 had
a significant effect on 11,6 secretion at 0.1 ng/ml, in agree-
ment with previously published data (7). However, optimal
concentrations ofIL7 induced -10-fold higher levels of IL-6
than optimal concentrations of IL10 (Fig. 2). Identical results
were obtained when 11,6 was assayed by either B9 assay or
by ELISA.
Monocytes Are Less Sensitive to 11,7 than Are T Lympho-
cytes. We have previously shown that IL7 costimulates the
proliferation ofhuman T cells and enhances CTL generation
at concentrations as low as 0.1 ng/ml (21, 23). To directly
compare the concentrations of IL-7 required to stimulate T
cellsversus monocytes, we used the same preparation of IL-7
and compared its ability to either induce IL-6 secretion by
monocytes or enhance CTL generation in human MLC (Table
2). As shown above (Fig. 2), 10 ng/ml or more of IL-7 was
required for the induction of IL-6 secretion and the optimal
effect was seen at 100 ng/ml. In contrast, as little as 0.1 ng/ml
of IL7 could enhance CTL generation and maximal effects
were seen at 10 ng/ml (Table 2). Thus, CTL precursors ap-
pear to display a -100-fold greater sensitivity to IL-7 than
monocytes.
Kinetics ofIL6 Induction by 11,7.
￿
Monocytes were stimu-
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Figure 2.
￿
Dose-response ofIL-7 induced 11,6 secretion. Monocyte cul-
tures were established with various concentrations of IL-7 or 11,10 and
supernatants collected after 36 h. IL6 levels were detected either by (A)
the B9 hybridoma growth factor assay, or (B) IL-6 ELISA.
Table 2.
￿
Difference in Sensitivity ofCTL Precursors and
Monocytes to IL-7 Stimulation
" MLC were supplemented with the indicated concentration ofIL-7 for
7 d and assayed for the ability to lyse specific PHA blasts from the stimu-
lator donor, as previously described (23). Data represent lytic activity
at a 0.2 culture fraction.
t Counter current elutriator-purified monocytes were incubated with the
indicated concentration of IL-7 and supernatants collected after 36 h and
assayed for IL-6 bioactivity.
lated with optimal concentrations of IL-7, IL1(3, or LPS and
supernatants were collected at various time points and as-
sayed for IL-6 activity. As shown in Fig. 3, low levels of IL6
were detectable in the supernatants of IL-7, IWO, or LPS-
stimulated monorytes as early as 2 h after the initiation of
culture. IL-6 was not detected in nonstimulated cultures at
any time point (data not shown). All three stimuli showed
similar kinetic profiles of IL-6 induction with optimal levels
of IL-6 being detected within 24 h. Again 11,7 was found
to be a more potent inducer of IL-6 secretion than 11,10.
11,4 Inhibits the Ability of 11,7 to Induce IL6 Secretion and
IL6 mRNA. 11,4 has been reported to inhibit both mono-
cyte function and cytokine secretion induced by mitogenic
stimuli such as LPS (4, 8, 9, 14-17) . We initially observed
that the addition of 1174 to PBMC cultures inhibited the ability
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Figure 3.
￿
Kinetics of 11,6 production by monocytes. Monocytes were
stimulated with 11,7 (100 ng/ml), 11,10 (100 ng/ml), or LPS (10,ug/ml)
for various time periods and supernatants collected and assayed for 11,6
bioactivity in the B9 assay.
IL-7
CTL activity
(percent lysis")
Monocyte secretion of
IL-6t
ng/ml U/ml
0 0.3 <1
0.1 8.9 <1
1 30 <1
10 61 1,920
100 47 5,923
1,000 ND 7,867Table 3 .
￿
IL-4 Inhibits the Ability of IL-7 and LPS to Induce
Monocytes to Secrete IL-6
IL-6
Monocytes were cultured with IL-7 (100 ng/ml) or LPS (10 pg/ml) either
in the presence or in the absence of IL-4 (50 ng/ml in Exp. 1 and 100
ng/ml in Exp . 2) . Supernatants were collected after 36 h and assayed
for IL-6 bioactivity .
of 11,7 to induce lymphokine-killer cell (LAK) activity (23) .
To determine whether IL-4 could also inhibit the production
of IL-6, we cultured purified monocytes with 1177 or LPS,
either alone or in the presence of IL4 . IL4 treatment alone
was unable to induce IL-6 secretion by monocytes, however
IL-4 was found to markedly inhibit the ability of either IL-7
or LPS to promote IL6 secretion (mean of 88% and 74%
inhibition, respectively) (Table 3) . Suppression of IL-7-induced
Figure 4 .
￿
11,4 inhibits the ability of IL7 and LPS to induce IL6mRNA
in monocytes . Monocytes were cultured with medium, IL7 (100 ng/ml),
or LPS (10 tag/ml) eitherwith (+) or without (-) IL4 (100 ng/ml) . After
4 h RNA was extracted and Northern analysis was performed with an
11,6 antisense RNA transcript probe .
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IL6 secretion could be seen at concentrations of 1174 as low
as 0.1 ng/ml (data not shown) . The inhibitory effects of ILA
on IL6 secretion were also apparent at themRNA level (Fig .
4) . The addition of 114 to monocytes stimulated with either
IL-7 or LPS significantly downregulated IL-6 mRNA .
11,7 induces IL1a, 11,1,8, and TNF-a Secretion by Mono-
cytes. We next investigated the ability of IL-7 to induce the
secretion of other cytokines by monocytes, namely IL1a,
IL10, and TNF-a . Monocytes were cultured for 36 h with
various concentrations of IL7 or 10 hg/ml of LPS, and su-
pernatants were collected and assessed for the presence of IL1a,
IL1(3, IL6, and TNF-a by cytokine-specific ELISAs . Super-
natants from monocytes cultured with medium alone or up
to 10 ng/ml of IL-7 contained nondetectable levels of all four
monokines (Table 4) . However, IL-7 at 100 ng/ml or greater
induced significant secretion of IL1a, IL1O, 11,6, and TNF-ce
by monocytes . Optimal concentrations ofIL-7 induced >100-
fold increases in production of all three cytokines .
11,7 Induces Monocyte/Macrophage Tumoricidal Activity .
Monocytes can be stimulated in vitro by LPS or certain
cytokines, such as GM-CSF, tobecome cytotoxic for selected
tumor cell lines (30, 31) . As a result, we assessed the ability
of IL-7 to promote monocyte/macrophage tumoricidal ac-
tivity against the A375 human melanoma cell line. Table 5
demonstrates that IL7 significantly enhanced monocyte/mac-
rophage tumoricidal activity, inducing a mean of43% cyto-
toxicity in three experiments compared to 55% and 63%
with GM-CSF and LPS-cultured monocytes, respectively .
11,7 Induces 11,6 Secretion in Whole Blood Cultures.
￿
Recently,
the ability of LPS to induce 11,6 and TNF-a in whole blood
cultures was described (32, 33) . This culture system more
closely resembles in vivo conditions than isolated PBMC or
monocytes and avoids any effects that may be attributed to
cell preparation, culture medium, FCS or adherence to plastic.
Therefore, we assessed the ability of cytokines, namely IL-7
Table 4 .
￿
IL-7 Induces Monocytes to Secrete IL-la, IL-1,8, and
TNF-a in Addition to IL-6
Cytokine production
Monocytes were incubated with the indicated concentration of rIL-7 or
LPS (10 Rg/ml) and supernatants collected after 36 h . Culture superna-
tants were assayed for IL-la, IL-113, IL-6, and TNF-a by specific ELISAs .
IL-7 IL-la IL-1/3 IL-6 TNF-a
ng/ml pg/ml
0 <1 <5 <3 <2
0.1 <1 <5 <3 <2
1 <1 <5 <3 <2
10 <1 <5 <3 10
100 202 1,572 8,964 1,050
1,000 527 2,586 12,714 1,170
LPS 372 2,860 11,606 2,370
Stimulus
Exp . 1
- IL-4 + IL-4
U/ml
Exp .
- IL-4
2
+ IL-4
Medium <1 <1 <1 <1
IL-7 19,220 3,665 2,437 106
LPS 16,343 6,176 10,143 1,502Table 5.
￿
IL-7 Induces Monocyte/Macrophage Tumoricidal Activity
Stimulus
￿
Exp. 1
￿
Exp. 2
￿
Exp. 3
IL-7 31 .4±1 .5 60.3±2.5 37.6±3.3
GM-CSF
￿
75 .2 ± 6.5
￿
49.3 ± 3.4
￿
40.5 t 1.9
LPS
￿
69 .9 t 6.0
￿
58.4 ± 1.9
￿
60.4 ± 4.3
Discussion
Percent cytotoxicity
IL-7 (100 ng/ml) was compared to, GM-CSF (100 ng/ml) andLPS (10
jug/ml) for its ability to induce monoryte/macrophage tumoricidal ac-
tivity as described in Materials and Methods. Data representpercent cytox-
icity ofmonocytescultured in cytokine or LPSas compared to monorytes
cultured in medium alone andaremean t SEMof sixreplicate cultures.
CPM forA375 cells cultured with no monocytes andA375 cellscultured
with nonstimulated monocytes were: Exp. 1, 19,286 and 18,903; Exp.
2, 34,655 and 28,119; Exp. 3, 39,303 and 31,491.
and 11,10, to stimulate IL1a,11,10, IL6, and TNF-oi produc-
tion in whole blood cultures. As shownin Table 6, cytokines
were not detected in whole blood cultured for 24 h in the
absence of a stimulus. As previously reported, LPS was a po-
tent stimulus for cytokine secretion in whole blood cultures.
In addition, high levels of IL-6 were detected in the plasma
from whole blood stimulated with IL-7 or ILlO. However,
in contrast to purified monocyte cultures where IL-7 was al-
most as potent a stimulus as LPS, IL-7 was a relatively poor
stimulus for rytokine production in whole blood. IL-7 also
induced IL1a and ILl/3 secretion in whole blood, though
TNF-a levels were only marginally above background.
Interleukin 7 has a number of biological effects on lym-
phocytes and lymphocyte precursors, including stimulating
the growth of pre-B cells, thymocytes, and mature T cells
(18-24). In the experiments reported herein, we demonstrate
that purified rIL7 also has potent effects on human periph-
eral blood monocytes. When IL7 was added to PBMC or
Whole bloodcultures were supplemented with IL-1/3 (100 ng/ml), IL-7
(100 ng/ml), or LPS (10 Ag/ml). After 24 h, plasma was isolated and
assessed for the presence of IL-1cr, IL-1/3, IL-6, and TNF-cr by specific
ELISAs.
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purified monorytes, it was found to stimulate the secretion
of high levels of IL6, IL1a, ILls, and TNF-a. In addition,
IL7 was a strong inducer of monocyte/macrophage-mediated
lysis of the A375 human melanoma cell line.
The activity of IL7 on monoryte rtokine secretion re-
sembles that of bacterial endotoxin, though we believe that
our results are not due to endotoxin contamination of our
rtokine preparations for the following reasons. First, our
cytokines are extensively purified and particular preparations
selected on the basis of their low endotoxin content (usually
<1 pg per Wg ofprotein). Second, heating of IL7 totally ab-
lated its ability to stimulate IL6 secretion and IL-6 mRNA,
whereas heating ofLPS had no effect on its activity on mono-
cytes (data not shown). Finally, IL7, at concentrations up
to 11~g/ml, was unable to induce IL6 secretion by the THP-1
monocytic cell line whereas LPS is a potent inducer of IL6
secretion by these cells (data not shown).
Dose-response studies revealed that relativelyhigh concen-
trations of IL7 (10 ng/ml or greater) were required to stimu-
late IL6 production by monorytes (Fig. 2). In contrast, we
have previously shown that far lower concentrations of IL7
(0.1-1 ng/ml) will enhance human T cell proliferation and
the generation of CTL in MLC (21, 23). The relatively high
concentrations of IL7 required to stimulate monocytes com-
pared to T cells might be explained on the basis ofthe partic-
ular receptors used by the different cell types. Both low and
high affinity binding of 11,7 to its receptor have been de-
scribed (25) . Alternatively, there may be differences in the
post receptor signaling pathways used by monocytes and T
cells. In support ofthis concept, we have recently shown that
IL7 induces macrophage inflammatory protein-1(3 mRNA
accumulation in human monorytes but not in purified T cells
(S. F. Ziegler, T W Tough, T. L. Franklin, R. J. Armitage,
K. H. Grabstein, and M. R. Alderson, manuscript submitted
for publication) .
IL-7, in addition to promoting IL6 production, induced
the secretion of IL1a, ILl0, and TNF-a by peripheral blood
monorytes. Thus, IL7 may have a very broad range of bio-
logical activities on the immune system, both directly and
via the cascade of cytokines that it induces. At this time it
is not clear whether the effect of 11,7 on the production of
IL6 by monocytes is direct or mediated via a rytokine cas-
cade. Conceivably, IL7 could function by inducing another
rtokine, for example IL 1, which could then in turn induce
IL6 secretion. However, we believe that this is unlikely since
the kinetics of induction of 11,6 secretion by IL-7 and I1,10
are identical and because 11,7 is a more potent inducer of
11,6 secretion than either IL1a or IL1a. We are currently
investigating whether any of the effects of IL7 on mono-
rytes are mediated via a rtokine cascade using neutralizing
antibodies against IL1ci, ILl0, and TNF-a.
Previous studies have demonstrated that IL4 inhibits IL1,
IL-6, and TNF gene expression and protein secretion induced
by mitogenic stimuli such as LPS (4, 8, 9, 14-17). In this
paper we extend these previous findings to show that IL4
also inhibits the ability of IL7 to induce monoryte cytokine
synthesis at both the mRNA and protein levels. Thus, our
data suggest that IL4 may be an important regulator of inffam-
Table 6.
Stimulus
Production of
IL-1a
Cytokines in Whole Blood
Cytokine production
IL-1(3 IL-6
Cultures
TNF-a
pglml
Medium <1 <5 <3 <2
IL-10 <1 - 432 5
IL-7 110 209 801 9
LPS 11,100 7,542 9,954 6,870mation induced by stimuli other than Gram-negative bac-
teria. We have previously demonstrated that 11,4 is a potent
inhibitor of the induction of LAK cells by either IL2 or Ilr7
and CTL generation by 11,2 (23, 27). Collectively, these data
suggest that 11,4 plays a central role in down regulating mul-
tiple facets of the immune response. Whether the ability of
IL4 to downregulate LAK cell induction and CTL genera-
tion is linked to its ability to inhibit cytokine secretion by
monocytes remains to be elucidated.
Incubation of monocytes with IL7 resulted in the activa-
tion of tumoricidal activity against the A375 melanoma cell
line (Table 5). Monocyte/macrophage tumoricidal activity is
thought to be mediated, at least in part, by the secretion of
soluble mediators such as TNF-a and 111 (35-37), though
cell-cell contact may be involved (38, 39). Therefore, the ability
of 11,7 to induce monocyte/macrophage tumoricidal activity
correlates well with its ability to induce Ma, IL10, and
TNF-a secretion by monocytes (Table 4). As such, IL7joins
GM-CSF as a rytokine that may be potentially useful for ac-
tivating monocytes in vivo to become lytic against certain
tumors.
In an attempt to more closely mimick the complexity of
in vivo conditions, we used the recently describedwholeblood
culture system (32, 33) and found that both IL-7 and 11,1/3
induced IL6 secretion that was detectable in the plasma within
24 h of stimulation. Thus, monocytes derived from circula-
tion, exposed to either IIr1 or IL7 in vivo, could conceivably
contribute to the elevated levels of serum IL6 observed after
various challenges to the immune system (40-42).
Whether 11,7 plays a role in the inflammatory immune
response in vivo via the production of IL6, 11,1a, ID10, and
TNF-a remains to be elucidated. However, our monocyte
data generated in vitro and results using whole blood cul-
tures suggest this is a distinct possibility, providing that mono-
cytes are exposed to the appropriate concentration of IL7 in
vivo. Localized environments in vivo, such as the bone marrow
or thymus where IL7 appears to be constitutively produced
(18), may provide the appropriate IL7 concentrations. Thus,
inhibitors of the effects of IL7 on monocytes, such as IL4
or the naturally occurring soluble version of the I1,7 receptor
(43), may prove to be useful therapeutically to regulate inflam-
matory immune responses.
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